Drug shows significant early promise in early, high-risk, HR-positive, HER2-negative breast cancer: Interim data indicate that adding abemaciclib to hormonal therapy reduces recurrence risk.

Subjects :: Cyclin-Dependent Kinase 4 antagonists & inhibitors
Cyclin-Dependent Kinase 6 antagonists & inhibitors
Disease-Free Survival
Drug Therapy, Combination methods
Female
Humans
Aminopyridines administration & dosage
Benzimidazoles administration & dosage
Breast Neoplasms drug therapy
Breast Neoplasms metabolism
Hormone Replacement Therapy methods
Neoplasm Recurrence, Local prevention & control
Protein Kinase Inhibitors administration & dosage
Receptor, ErbB-2 metabolism
Receptors, Estrogen metabolism

Full Text Access

Tools